Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84. https://doi.org/10.1101/gad.314617.118. (PMID: 30275043; PMCID: PMC6169832).
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239. (PMID:22437870;PMCID:PMC4856023).
3. National Cancer Institute. Immune Checkpoint Inhibitors. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors#:~:text=Immunotherapy%20drugs%20called%20immune%20checkpoint,checkpoint%20protein%20called%20CTLA%2D4 (Accessed on 04 Nov 2023).
4. Jácome AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, Prolla G, Garicochea B. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. JAMA Netw Open. 2021;4(12): e2136128. https://doi.org/10.1001/jamanetworkopen.2021.36128. (PMID:34870682;PMCID:PMC8649834).
5. Carretero-González A, Otero I, Lora D, Carril-Ajuria L, Castellano D, de Velasco G. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Oncoimmunology. 2021;10(1):1878599. https://doi.org/10.1080/2162402X.2021.1878599. (PMID:33680572;PMCID:PMC7906255).